Studies have correlated elevated plasma factor VIII (FVIII) with thrombosis; however, it is unclear whether elevated FVIII is a proinflammatory biomarker, causative agent, or both. We raised FVIII levels in mice and measured the time to vessel occlusion (TTO) following ferric chloride-induced injury.
INTRODUCTION
Elevated factor VIII (FVIII) levels have been consistently and positively associated with primary and recurrent venous thromboembolism (VTE) [Odds Ratio (OR) 2.0 -10.8]. [1] [2] [3] [4] [5] [6] [7] [8] For example, the Leiden Thrombophilia (LETS) Study 6 showed FVIII concentrations over 1.5 U/mL led to an OR greater than 5, and Kyrle et al. 4 showed relative risk of VTE recurrence was 6.6 in patients with FVIII levels over 2.34 U/mL. FVIII concentrations over 2 U/mL have been associated with an OR of VTE recurrence as high as 10.8. 3 In contrast to VTE, the role of FVIII in arterial thrombosis is controversial. Using broad definitions of coronary heart disease (CHD) encompassing atherosclerosis, angina, transient ischemic attack, acute and non-acute myocardial infarction (MI) and death, several studies have associated elevated FVIII with CHD and/or stroke, with OR ranging from 1.2 -2.65. [9] [10] [11] [12] However, associations between FVIII activity and CHD 13 or ischemic heart disease 12 were lost following multivariate adjustment for diabetes and von
Willebrand factor (vWF) levels, respectively. Importantly, since FVIII is increased in diseases that induce an acute phase response, including myocardial infarction 14 , surgery 15 , and sepsis 16 , it is unclear whether FVIII's association with either venous or arterial thrombosis simply reflects an ongoing prothrombotic inflammatory process, or is a direct, causative mechanism in the thrombosis etiology and therefore a therapeutic target, or both.
Studies examining the role of elevated FVIII in murine thrombosis models have also shown discord.
Mice infused with recombinant human FVIII to 250% of normal demonstrate FVIII accumulation in thrombi and significantly enhanced thrombus size after photochemical (Rose Bengal)-induced carotid injury. 17 In addition, inhibiting FVIII activity with a monoclonal antibody blocks thrombus formation in a murine inferior vena cava (IVC) stenosis model and in baboons implanted with arteriovenous shunts. 18, 19 In contrast, elevated FVIII (20% murine FVIII plus 280% infused human FVIII) does not promote microvascular or vena cava occlusion in vWF-deficient mice. 20, 21 Together, these studies suggest a role for FVIII in arterial and venous thrombosis, but that additional modifiers such as vWF, modulate its relative impact.
In the current study, we used murine models of thrombosis in the vein and artery to assess the role of elevated FVIII in thrombus formation and stability, and used ex vivo and in vitro methods to identify the operant biochemical mechanisms. Elevated FVIII augmented thrombus formation and stability after mild, but not severe ferric chloride (FeCl 3 ) injury. FVIII's effects were manifest via its ability to increase thrombin generation and accelerate platelet aggregation initiated by low, but not high TF 
METHODS

Proteins and materials
Dulbecco's modified Eagle's Medium with high glucose/2 mM L-glutamine, 0.05% trypsin/ethylenediamine tetraacetic acid, and phosphate-buffered saline (10 mM phosphate pH 7.1, 150 mM NaCl) were from Gibco (Grand Island, NY). Human monoclonal purified FVIII (Hemofil M) was from Baxter (Deerfield, IL). FVIII-deficient (Hemophilia A, <1% FVIII activity) platelet-poor plasma (PPP) was from HRF Inc (Raleigh, NC). Kontact (aPTT reagent) was from Thermo Fisher Scientific Tenecteplase was the generous gift of Genentech (San Francisco, CA). Corn trypsin inhibitor and factor X were from Haematologic Technologies Inc (Essex Junction, VT). Contact-inhibited normal pooled plasma (NPP) was prepared from whole blood from 40 healthy subjects (50% female, 68% nonCaucasian) in a protocol approved by the UNC Institutional Review Board, as previously described.
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Murine Thrombosis and Thrombolysis Models
Procedures were approved by the UNC Institutional Animal Care and Use Committee. Mice (6) (7) (8) week old male C57BL/6, Charles River Laboratories, Raleigh, NC) were anesthetized with 1.5-2% isofluorane in 2% oxygen, and the left saphenous vein was exposed under a SZX12 dissecting microscope (Olympus, Tokyo, Japan) and catheterized as described. 22 17 , has comparable cofactor activity as murine FVIII 17 , and promotes coagulation after tail clipping and vessel injury in hemophilic mice 17, [24] [25] [26] [27] . In addition, previous studies 28, 29 and our findings (FVIII activity assay, described below) show FVIII has sufficient half-life in murine circulation for these experiments. The endogenous FVIII concentration in mice (1 U/mL, 100%) 30 was raised by infusing human FVIII to 285% (total murine plus human FVIII) of normal, consistent with levels associated with thrombosis in humans. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] The saphenous vein and carotid artery thrombosis models were performed as described. 22 Briefly, the right saphenous vein was exposed, treated with 5% FeCl 3 (0.31 M FeCl 3 on 0.5x2 mm filter paper) for 3 minutes, and washed with warm saline. Saphenous vein blood flow was monitored auditorily by Doppler ultrasonic flow probe. On separate mice, the right common carotid artery was exposed after midline cervical incision, dried, treated with 10% FeCl 3 (0.62 M on 0.5x0.5 mm filter paper) for 3 or 2 minutes, and washed with warm saline. Following injury, carotid blood flow was monitored via Doppler transonic flow probe. In both models, the time to occlusion (TTO) was defined as the time between FeCl 3 administration to the indicated vessel and lack of flow for 60 consecutive seconds.
Experiments were stopped at 45 minutes if no occlusion occurred. Embolization was defined as a rapid increase in blood flow of at least 0.2 mL/min in the 5 minutes after stable occlusion occurred. Either 10 minutes after stable occlusion or after 45 minutes without stable occlusion, blood was drawn from the IVC into 3.2% sodium citrate and processed to platelet-poor plasma (PPP) by centrifugation at 5,000xg for 10 minutes.
Thrombolysis was assessed in mice subject to 3-minute FeCl 3 carotid artery thrombosis as described. 22 Briefly, after 5 consecutive minutes of blood flow below 0.1 mL/min, mice were infused with tenecteplase (5 mg/kg) through the saphenous vein catheter while continuously monitoring blood flow.
FVIII Activity Assay
Factor VIII activity was measured in PPP from FVIII-infused mice not subject to thrombosis. Five and 30 minutes after FVIII infusion, blood was drawn from the IVC into 3.2% sodium citrate and processed to PPP. Murine PPP was mixed with human FVIII-deficient PPP (5% murine PPP and 95%
FVIII-deficient PPP), and clotting was initiated with Kontact aPTT reagent (40% total volume) and 
Measurement of circulating thrombin-antithrombin (TAT) complexes
Citrated blood samples were drawn from the IVC of mice subject to the FeCl 3 carotid artery thrombosis model. TAT levels were measured by ELISA (Enzygnost TAT micro ELISA, Siemens, Deerfield, IL). Samples showing hemolysis were excluded.
Cell culture
Primary human aortic smooth muscle cells (SMC, Lonza Walkersville, Walkersville, MD) were cultured as directed in 5% CO 2 at 37°C, and used between passages 3-6 to reduce phenotypic drift.
Phospholipid vesicles
Phosphatidylcholine (egg), phosphatidylethanolamine (soy), and phosphatidylserine (porcine brain)
were from Avanti Polar Lipids (Alabaster, AL). Large unilamellar vesicles (41% phosphatidylcholine/44% phosphatidylethanolamine/15% phosphatidylserine) were made by extrusion, as described.
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TF Activity
TF activity was measured by chromogenic substrate cleavage on a SpectraMax Plus 340 plate reader in the presence and absence of inhibitory anti-TF antibody or isotype control (10 µg/mL HTF-1 or MOPC-1, respectively), as described.
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Thrombin generation
Thrombin generation was measured by calibrated automated thrombography using a Fluoroskan Ascent fluorometer (ThermoLabsystem) as described. 33 Thrombin generation parameters (lag time and peak) were calculated using Thrombinoscope software Version 3.0.0.29 (Thrombinoscope BV, Maastricht, Netherlands). The thrombin generation rate was calculated by dividing peak height by the difference from time to peak and lag time.
H&E Staining and Immunohistochemistry
Fixed tissues were dehydrated and paraffin-embedded, and consecutive, five-micron sections cut and mounted at the UNC Lineberger Comprehensive Cancer Center Animal Histopathology Core.
Hematoxylin and eosin (H&E) staining was used to visualize the thrombus. Immunohistochemistry (IHC) for fibrin(ogen) was performed with monoclonal antibody 59D8, as described. 22 Negative controls were stained simultaneously in the absence of primary antibody.
Platelet Aggregation
Platelet aggregation was performed as described on a Chrono-Log Optical Aggregometer 470 (Havertown, PA). 
Statistical Methods
For TTO, conditions were compared pairwise by a log-rank test due to censored observations at 45 minutes (no stable occlusion). For TATs and embolization analysis, conditions were compared by Mann-Whitney tests to account for both unequal variance and non-normality of outcomes. For in vitro thrombin generation assays, significant differences between groups were identified by a one-way analysis of variance (ANOVA) with homogeneity tests and residual plots to check statistical assumptions. To analyze the effect of FVIII concentration on thrombin generation parameters (lag time, rate and peak height), a one-sided Dunnett's post-hoc test using 1 U/mL FVIII (100% FVIII) as the index group (on SMC of varying confluency, as indicated) was used, with a controlled type-I error rate no larger than 0.05 in the multiple testing between experimental and index groups. For platelet aggregation data, normalized lag times where ratios were calculated between 200%, 300%, and 400% to 100% FVIII were tested by a one-sided t-test with a null hypothesis no smaller than 1. Bivariate correlation analyses between TTO, TAT, and number of emboli were presented in Pearson's coefficient (denoted as R) that indicates the degree of linear dependence. Statistical analyses were performed using
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From SPSS 16.0 (SPSS Inc., Chicago IL). P-values less than 0.05 were considered significant. Hemofil M contains only trace human vWF (0.083 μ g vWF/U FVIII). 34 These findings indicate FVIII's effect was specific and confirm a direct, pathogenic contribution of elevated FVIII in a murine model of thrombosis in a vein.
RESULTS
Elevated FVIII shortens the TTO in a saphenous vein thrombosis model.
Elevated FVIII shortens the TTO following short (2-minute), but not longer (3-minute), FeCl 3 treatment to the carotid artery.
In contrast to VTE, the role of FVIII in arterial thrombosis is unclear. We therefore tested the ability of FVIII to accelerate arterial clotting following 3-minute FeCl 3 application to the carotid artery.
Representative flow tracings are shown in Figure 1A -1B. Control mice developed occlusive thrombi in 8.1 minutes (median, Figure 1F) . Surprisingly, although mice with hypercoagulability due to elevated fibrinogen demonstrate significantly shortened TTO under these conditions 22 , mice with elevated FVIII did not (7.1 minutes median, p=0.6, Figure 1F ).
Given studies demonstrating differential sensitivity to intrinsic pathway components with extent of FeCl 3 injury 35, 36 , we then tested a second set of conditions in which FeCl 3 was applied to the carotid artery for only 2 minutes. Representative flow tracings are shown in Figure 1C -1E. Compared to 3-minute FeCl 3 injury, control mice took significantly (p<0.005) longer to form stable thrombi following 2-minute FeCl 3 injury (13 minutes, median, Figure 1F ). Interestingly, unlike the 3-minute injury model, mice with elevated FVIII exhibited a significantly (p<0.005) shorter TTO than control mice in this 2-minute injury model (7.8 minutes, median, Figure 1F Figure 2 ). TAT levels in control mice were significantly (p<0.05)
higher following 3-minute injury than 2-minute injury, indicating 3-minute FeCl 3 application causes higher procoagulant activity than 2-minute FeCl 3 application. Compared to controls, elevated FVIII did not increase TAT levels in the 3-minute injury model (222±85.2 ng/mL, p=0.5), but caused significantly higher TAT levels than controls after 2-minute (175±115 ng/mL, p<0.05) FeCl 3 application ( Figure 2 ).
Across all mice, TAT levels correlated with TTO values (R=0.388, p=0.055), suggesting differences in TTO resulted from differential procoagulant activity at the site of injury.
Elevated FVIII increases thrombin generation in an in vitro model of mild, but not severe, vascular injury.
Given findings associating TTO with circulating TAT levels, we hypothesized that the duration of For
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We then determined the effect of FVIII on thrombin generation at each confluency level by incubating SMCs with recalcified, lipidated NPP spiked with FVIII [to 2 U/mL (200%), 3 U/mL (300%) and 4 U/mL (400%), final], Figure 3 ). Elevated FVIII non-significantly shortened the lag time in reactions with SMCs at all confluencies ( Figure 3G) ; this effect was more pronounced at lower SMC confluencies. At 100% confluency (high TF), FVIII had no effect on the rate or peak height (Figure 3H-3I ). At 60% confluency (medium TF), 400% FVIII increased the rate (p<0.05), but not peak height. At 20% confluency (low TF), both 300% and 400% FVIII significantly (p<0.005) increased the rate and peak height (Figure 3H-3I) . The significantly faster rate of thrombin generation in 20% SMC ( Figure   3H 
Elevated FVIII does not alter thrombus morphology or increase thrombus fibrin(ogen) content.
We previously showed hyperfibrinogenemic mice exhibit increased thrombus fibrin(ogen)
deposition. 22 We therefore tested whether elevated FVIII and its subsequent increase in thrombin generation in the 2-minute injury model similarly increased thrombus fibrin(ogen) content. H&E staining showed similarly extensive, occlusive thrombi with similar vessel diameters, containing distinct regions of anucleate, proteinaceous material and erythrocytes in thrombi from control and FVIII-infused mice (Supplemental Figure S1 ). IHC of thrombi from both control and FVIII-infused mice demonstrated weak fibrin staining concentrated primarily at the luminal edge of proteinaceous regions.
There were no obvious differences in fibrin staining intensity between control and FVIII-infused mice (Supplemental Figure S1 ), suggesting thrombus fibrin content was unchanged by elevated FVIII.
Together, these findings indicate FVIII did not shorten the TTO by increasing thrombus fibrin content.
Elevated FVIII accelerates platelet aggregation when triggered with low, but not high, TF.
To determine whether FVIII-dependent, increased thrombin generation accelerated platelet incorporation into the thrombus, we raised FVIII levels in human PRP with additional human FVIII, and triggered platelet aggregation with TRAP, collagen, ADP, or TF. Elevated FVIII had no effect on platelet aggregation initiated by TRAP, collagen, or ADP, showing that FVIII does not impact platelet function in the absence of thrombin generation (data not shown). In reactions triggered by TF, FVIII
org From had no effect on either the rate or maximum amplitude of platelet aggregation ( Figure 4A ).
Interestingly, however, whereas elevated FVIII had no effect on the lag time in reactions triggered with high TF, elevated FVIII dose-dependently shortened the lag time of platelet aggregation in reactions triggered by low TF (p<0.05, Figure 4A-4B) . These data are consistent with the FVIII-dependent shortening in TTO after 2-, but not 3-minute injury, and suggest elevated FVIII shortened the TTO by accelerating platelet activation at the injury site.
Elevated FVIII increases thrombus stability following mild, but not severe, vascular injury.
Finally, since both shorter TTO and higher procoagulant activity have previously been associated with increased thrombus stability 22, 33, 39 , we examined thrombus stability in the carotid artery of mice as functions of both duration of FeCl 3 treatment and FVIII level. Representative flow tracings from experiments with control (saline-infused) mice after 3-and 2-minute injury are shown in Figures 5A and 5B, respectively. All mice treated with FeCl 3 for 3 minutes demonstrated stable occlusion (<0.1 mL/min blood flow for 5 consecutive minutes), whereas some mice treated with FeCl 3 for 2 minutes did not. We quantified clot stability by counting the number of embolic events (rapid increase in blood flow of at least 0.2 mL/min) in the 5 minutes following the TTO. Mice produced significantly (p<0.05) more emboli after 2-minute FeCl 3 injury than 3-minute injury ( Figure 5C ). In the 2-minute injury model, FVIII-infused mice produced significantly (p<0.05) fewer emboli than control mice; however, there was no difference in number of emboli between control and FVIII-infused mice after 3-minute injury ( Figure   5C ). Across all mice, the number of emboli was significantly, positively-associated with TTO values (R=0.495, p=0.019) and significantly, negatively-associated with TAT values (R=0.614, p=0.005).
Since control and FVIII-infused mice thrombosed with FeCl 3 for 3 minutes demonstrated stable occlusion, we further examined thrombus stability by infusing these mice with the tissue plasminogen activator derivative, tenecteplase, as described. 22 Consistent with their similar TTO, TATs, and number of emboli, there was no difference in tenecteplase-induced thrombolysis; all mice showed complete return of blood flow (data not shown). In total, these data suggest longer FeCl 3 treatment (increased vascular injury) produces highly stable thrombi irrespective of intrinsic pathway components, whereas shorter treatment (less injury) produces unstable thrombi. Elevated FVIII stabilizes thrombi after mild, but not severe vascular injury.
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DISCUSSION
Epidemiologic studies have repeatedly correlated elevated plasma FVIII levels with VTE. [1] [2] [3] [4] [5] [6] [7] [8] However, the role of FVIII in arterial thrombosis is controversial. In addition, for both venous and arterial thrombosis, it is unclear whether elevated FVIII is merely a proinflammatory biomarker 14, 15, 16 , a causative mechanism in the disease etiology, or both. We acutely elevated FVIII in mice and examined their susceptibility to thrombosis, and used ex vivo and in vitro methods to elucidate biochemical mechanisms for the observed effects. Our findings confirm an etiologic, prothrombotic role for elevated FVIII in veins. Moreover, our findings show elevated FVIII: 1) shortened the TTO after short (2-), but not longer (3-)minute FeCl 3 treatment to the carotid artery, 2) increased thrombin generation in mice after short but not long FeCl 3 treatment, 3) augmented the thrombin generation rate and peak in vitro with low, but not high, TF (SMC) exposure, 4) accelerated the onset of platelet aggregation initiated by low TF, and 5) promoted the formation of more stable thrombi (fewer emboli) following short, but not long injury in mice. Together, these findings demonstrate an etiologic role for FVIII in thrombosis, but suggest dependence of plasma FVIII activity on the extent of vascular injury.
We and others have previously shown dose-dependent effects of TF activity on thrombin generation in vitro. 33, 38, 40 Our data quantifying circulating TAT complexes in mice subject to 2-and 3-minute produced a more severe injury with higher exposure of cellular procoagulant activity. Our findings do not rule out the possibility that longer FeCl 3 treatment also increased platelet deposition by exposing more subendothelial collagen than the shorter injury. However, we were able to recapitulate effects of longer and shorter FeCl 3 treatment on platelet aggregation and thrombin generation by varying the soluble TF concentration ( 38 and Figure 4 ), or SMC confluency in vitro (Figure 3 ), suggesting differential exposure of procoagulant (TF) activity differentiates these treatments. Any effect on platelets of collagen exposure between the 2-and 3-minutes injury models would occur distinctly from, but potentially in addition to, effects of procoagulant activity. Importantly, our observation that TAT measurements correlate with thrombus formation (TTO) and stability measurements provides a means of quantifying differences in extent of vascular injury in different in vivo models. This information may enable reconciliation of differences in outcome measures between studies using different thrombosis models. While previous studies hypothesized increased FeCl 3 injury reduces sensitivity to intrinsic factors by increasing TF/VIIa activity 35, 36 , our study is the first to show a mechanism for differences in mild and severe FeCl 3 injury: differential procoagulant activity, measured by TAT complex formation. Indeed, the sensitivity of intrinsic pathway components is perhaps best demonstrated by differences in the prothrombin time (PT) and partial thromboplastin time (PTT) tests.
Whereas the PT detects clotting deficiencies due to extrinsic and common pathway components, its high TF concentrations mask effects of factors VIII or IX deficiency. Lower TF concentrations in a PTT reveal FVIII or factor IX deficiencies. To our knowledge, our study is the first to demonstrate an interaction between extent of vascular injury and effect of plasma hypercoagulability in vivo. This interaction suggests more severe injury (longer application of FeCl 3 ) exposes a sufficiently high amount of TF activity to negate effects of elevated FVIII. In contrast, less severe injury (shorter application of FeCl 3 ) exposes less TF activity, enabling a role for FVIII in procoagulant activity.
Our data demonstrating a etiologic role for FVIII in thrombosis are consistent with previous findings that elevated FVIII promotes Rose Bengal-induced thrombosis 17 , stabilizes thrombi (decreases microvascular thrombus embolization) 20 , and normalizes the blood clotting time in vWF-deficient mice 20 , and that FVIII inhibition blocks thrombus formation in murine and baboon thrombosis models 18, 19 . By comparing severe and mild vascular injuries, our study illuminates specific contributions of vascular procoagulant activity not apparent in the prior reports. Our findings differ somewhat from observations that elevated FVIII (to 250%) increases thrombus size. 17 In our study, thrombi in control and FVIII-infused mice appeared morphologically similar, with no obvious differences in thrombus size (vessel diameter) or final fibrin content. Differences between these findings may reflect the injury model (FeCl 3 versus Rose Bengal) and/or the method of quantification (IHC of fully-formed occlusive thrombi versus transillumination during thrombus formation which
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From reflects the rate of thrombus growth). 17 Although we were unable to measure the rate of thrombus growth in vivo, our in vitro data indicate faster platelet activation ( Figure 4 ) and slightly faster fibrin polymerization (data not shown), consistent with their findings. Brill et al. previously showed that elevated FVIII (300% of normal, 20% murine FVIII and 280% human FVIII) does not promote venous occlusion in vWF-deficient mice 20, 21 , suggesting vWF is necessary for at least part of FVIII's procoagulant effects. Our study extends these findings by demonstrating a critical role for the extent of vascular injury in FVIII-dependent thrombin generation and thrombogenesis.
Besides elevated FVIII, epidemiologic studies have also correlated elevated fibrinogen levels (hyperfibrinogenemia) with thrombotic risk.
2,8,44
We previously showed that like elevated FVIII, elevated fibrinogen shortens the TTO in both saphenous vein and carotid artery and increases thrombus stability. 22 However, in contrast to elevated factor VIII, hyperfibrinogenemia shortens the TTO in the 3-minute FeCl 3 carotid injury model. Moreover, elevated fibrinogen increases thrombus fibrin content 22 , whereas elevated FVIII did not. Rather, elevated FVIII accelerated platelet aggregation in a low TF/thrombin generation-dependent mechanism. Since we and others have shown that high thrombin concentrations produce dense fibrin networks that are resistant to lysis 33, 39, 45 , elevated FVIII may also alter the structure of fibrin present in the thrombi of mice treated with FeCl 3 for 2 minutes.
Unfortunately, while IHC provides quantitative information about fibrin content, which was not altered by elevated FVIII (Supplemental Figure S1) , it does not reveal information about fibrin network structure (individual fiber thickness or density). Regardless, the differences between these findings demonstrate fundamental differences in the hypercoagulable mechanisms of elevated fibrinogen and elevated FVIII, and suggest antithrombotic strategies could be tailored for a specific hypercoagulability (blocking thrombin generation/activity versus blocking fibrin formation). 46 Our findings on the relationship between vascular injury and effect of FVIII on thrombosis inform epidemiologic studies showing either moderate or no relationship between FVIII and arterial thrombosis. 9, 10, 12, 13 Using the presence of carotid plaque as a marker of mild or moderate disease, Pan et al. 9 showed a significant association between heart disease and FVIII level (OR=2.65). In contrast, using a broad definition of CHD that encompassed both mild and severe disease (definite, probable, or silent MI or definite CHD death), Folsom et al. 13 found no correlation between CHD and FVIII activity (OR=1.0). Interestingly, plaque rupture is associated with exposure of high levels of TF (reviewed in 47 ). In light of our data, differences in the conclusions of these studies may reflect the severity of the study inclusion event. FVIII activity likely contributes to thrombosis only when there is mild TF exposure, and is unlikely to contribute after a severe event that exposes high TF, such as plaque rupture.
Given a causative role for FVIII in thrombosis, it is tempting to speculate about the potential efficacy of antithrombotic strategies that target FVIII activity in venous and arterial thrombosis.
Elevated FVIII is strongly (2-to 10.8-fold) associated with VTE, and partial inhibition of FVIII activity with a monoclonal antibody blocks thrombus formation in a murine IVC stenosis model and in baboons implanted with arteriovenous shunts. 18, 19 In addition, patients with hemophilia A are protected from venous thrombosis. 48 These data and our own findings in the saphenous vein thrombosis model suggest FVIII inhibition may protect against VTE. However, hemophilia patients are only partially protected against ischemic heart disease 49 and epidemiologic studies inconsistently associate elevated FVIII with arterial thrombosis. Together with our data, these observations suggest FVIII inhibition would have only moderate efficacy in preventing arterial events triggered by high TF exposure.
This study has potential limitations. First, we used human FVIII to increase circulating levels in the mouse. However, our data and published studies demonstrate human FVIII binds murine vWF 17 , has comparable cofactor activity as murine FVIII 17 , is stable in murine circulation 28, 29 , is incorporated into murine clots 17 , is inactivated by murine activated protein C (Steve Pipe, personal communication), and supports clot formation in mice 17, [24] [25] [26] [27] . Second, the FeCl 3 /saphenous vein injury model is not commonly used as a model of venous thrombosis; however, our findings are consistent with published data from other venous models and effectively demonstrate the pathological activity of elevated human FVIII in thrombi formed in murine veins. [17] [18] [19] Finally, the FeCl 3 thrombosis model does not fully recapitulate the inflammatory process associated with atherosclerosis or plaque rupture in humans or mice, but rather, models acute thrombosis following vascular injury. However, FeCl 3 exposes SMC TF and produces platelet-rich thrombi similar to those seen in arterial clots. 37, 47, 50 In conclusion, our results show that both vascular damage and plasma hypercoagulability modulate thrombogenesis. Following limited arterial injury, FVIII directly promotes thrombosis via increased thrombin generation resulting in accelerated platelet activation and increased thrombus stability.
Elevated FVIII does not promote thrombosis following severe vascular injury. These findings provide a rationale for the controversy surrounding the role of FVIII in arterial thrombosis; in mice, FVIII's prothrombotic effects depend on the extent of injury that exposes procoagulant cells and triggers thrombin generation. Although few diagnostic algorithms simultaneously consider markers of tissue damage and plasma hypercoagulability when assessing thrombosis risk, integrating these pieces of 
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